Organisation paid for research Program year 2025 Source: CMS Open Payments

Clinical Neuroscience Solutions, Inc.

Neither a doctor nor a teaching hospital

Research payments

$2,720,522

930 payments

Through program year 2025, Clinical Neuroscience Solutions, Inc. is reported as receiving $2,720,522 in research payments, across 930 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $387,956 35
2024 Research $67,498 330
2023 Research $19,171 119
2022 Research $10,295 162
2020 Research $106,665 87
2019 Research $2,128,937 197

Breakdown

Who paid Research payments · program years 2019–2025
  1. Romark Laboratories, LC $1,793,539 4 payments
  2. Alkermes, Inc. $421,660 215 payments
  3. Axsome Therapeutics, Inc. $387,506 20 payments
  4. Alnylam Pharmaceuticals Inc. $84,052 604 payments
  5. Rhodes Pharmaceuticals L.P. $14,889 2 payments
  6. Swing Therapeutics, Inc. $12,638 6 payments
  7. Sunovion Pharmaceuticals Inc. $3,962 76 payments
  8. Teva Pharmaceuticals USA, Inc. $1,206 2 payments
  9. Amgen Inc. $1,070 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection $1,430,130 2 payments
  2. A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms $387,506 20 payments
  3. A Phase III Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide and Nitazoxanide Plus Oseltamivir in the Treatment of Acute Uncomplicated Influenza $363,409 2 payments
  4. A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder $354,095 178 payments
  5. A Phase 3b Extension Study of Adjunctive ALKS5461 in the Treatment of Refractory Major DepressiveDisorder $67,565 37 payments
  6. A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) $58,079 428 payments
  7. Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) $24,278 132 payments
  8. A 12-Month Open Label Safety Study of Methylphenidate Hydrochloride Extended-Release Capsules Aptensio XR in Children Ages 4-5 Years Diagnosed with Attention-DeficitHyperactivity Disorder ADHD $14,889 2 payments
  9. PROSPER-FM": Prospective Study to Evaluate a Digital Regimen for Fibromyalgia Management $12,638 6 payments
  10. A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 Depression $3,237 60 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record